Mani Foroohar
Stock Analyst at Leerink Partners
(2.25)
# 2,630
Out of 4,868 analysts
164
Total ratings
48.31%
Success rate
-7.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Downgrades: Market Perform | $37 → $8 | $2.70 | +196.30% | 11 | May 28, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $19 → $18 | $3.91 | +360.36% | 3 | Mar 24, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $5.03 | +19.28% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $4.13 | +553.75% | 9 | Jan 13, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $17.81 | +304.27% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $1.38 | +1,131.88% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $50.39 | -2.76% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $41.73 | +10.23% | 15 | Oct 17, 2024 | |
| WVE Wave Life Sciences | Maintains: Outperform | $20 → $22 | $6.57 | +234.86% | 6 | Oct 16, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $53 → $62 | $37.41 | +65.73% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $14.61 | -11.02% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $20.46 | +41.74% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $230 | $20.08 | +1,045.42% | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $5.44 | -26.40% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.43 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $3.06 | +913.07% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.59 | +1,092.30% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $15.32 | +161.10% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $111 → $93 | $25.90 | +259.07% | 17 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $9.20 | +813.04% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.22 | +215.32% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $16.76 | +359.43% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $309.70 | -53.83% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.89 | +1.95% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $44.25 | +71.75% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.34 | +2,437.31% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $2.24 | +792.86% | 6 | Jul 23, 2021 |
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Market Perform
Price Target: $37 → $8
Current: $2.70
Upside: +196.30%
Lexeo Therapeutics
Mar 24, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $3.91
Upside: +360.36%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $5.03
Upside: +19.28%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $4.13
Upside: +553.75%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $17.81
Upside: +304.27%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $1.38
Upside: +1,131.88%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $50.39
Upside: -2.76%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $41.73
Upside: +10.23%
Wave Life Sciences
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $6.57
Upside: +234.86%
Ionis Pharmaceuticals
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $37.41
Upside: +65.73%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $14.61
Upside: -11.02%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $20.46
Upside: +41.74%
Jun 24, 2024
Maintains: Outperform
Price Target: $165 → $230
Current: $20.08
Upside: +1,045.42%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $5.44
Upside: -26.40%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $8.43
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $3.06
Upside: +913.07%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.59
Upside: +1,092.30%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $15.32
Upside: +161.10%
Feb 24, 2023
Downgrades: Underperform
Price Target: $111 → $93
Current: $25.90
Upside: +259.07%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $9.20
Upside: +813.04%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.22
Upside: +215.32%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $16.76
Upside: +359.43%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $309.70
Upside: -53.83%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.89
Upside: +1.95%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $44.25
Upside: +71.75%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.34
Upside: +2,437.31%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $2.24
Upside: +792.86%